Vivos Therapeutics Announces Closing of Exercise of Warrants for $4.64 Million Gross Proceeds
January 20, 2026 17:31 ET | Source: Vivos Therapeutics, Inc LITTLETON, Colo.,…
Context Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 16, 2026 16:05 ET | Source: Context Therapeutics Inc. PHILADELPHIA, Jan.…
CAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
January 16, 2026 16:05 ET | Source: CAMP4 Therapeutics CAMBRIDGE, Mass., Jan.…
Monte Rosa Therapeutics Announces Pricing of $300 Million Underwritten Public Offering
BOSTON, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (“Monte…
Onco3R Therapeutics Appoints Lawrence Blatt as Chair of the Board for Onco3R Therapeutics
Leuven, Belgium. January 8, 2026. Onco3R Therapeutics, a clinical-stage immunology and oncology…
Engitix Announces $25 Million Series A Extension Financing by Existing Investor Mike Platt to Advance ECM-Targeted Therapeutics in Solid Tumors and Fibrosis
Company has built one of the largest proprietary extracellular matrix (ECM) datasets…
Day One Completes Acquisition of Mersana Therapeutics
Acquisition expands Day One’s pipeline with clinical-stage antibody drug conjugate (ADC) emiltatug…
Akari Therapeutics Issues 2025 End of Year Letter to Shareholders
December 30, 2025 09:15 ET | Source: Akari Therapeutics Plc TAMPA, Fla.…
Transcenta Therapeutics Announces Strategic Collaboration and Non-exclusive Licensing Agreement to Advance Integrated Continuous Biomanufacturing and Expand Global Access to Affordable Biologics
December 28, 2025 19:00 ET | Source: Transcenta PRINCETON, N.J. and HANGZHOU,…
Biosplice Therapeutics Announces First Patient Dosed in InvestigatorInitiated Phase 1 Clinical Trial of Cirtuvivint and Olaparib in BRCA/HRD PlatinumResistant Ovarian Cancer
SAN DIEGO, Dec. 22, 2025 (GLOBE NEWSWIRE) -- Biosplice Therapeutics, Inc. (“Biosplice”),…
